

NCE Programs - Pipeline



Product	Route of Administration	Indication	Research	Preclinical	Phase 1	Phase 2	Phase 3	Market
SUN-597	Nasal	Rhinitis						
SUN-597	DPI	Asthma						
SUN-597	Dermal	Dermatoses						
SUN-597	Ophthalmic	Allergic Conjunctivitis						
SUN-K706	Oral	Chronic Myelogenous Leukemia (CML)						
SUN-L731	Oral	Asthma/ Allergic Rhinitis						
SUN-1334H	Oral	Allergic Diseases						
SUN-1334H	Ophthalmic	Allergic Conjunctivitis						
SUN-09	Oral	Spasticity						
SUN-44	Oral	Neuropathic Pain						

The deployment of the balance amount of Rs. 965.87 million is therefore now proposed to include utilisation on clinical trial activities for all products/ technologies of the Company, such as S0597 nasal, latanoprost plus timolol combination eye drops, and dry powder inhaler, in the following manner:

Proposed revised Objects:

(₹ in million)

Sr. No.	Fund Requirements	Amount
1.	Pharmaceutical research and development activities - Funding clinical trials in India or USA, on any existing and/or future product/technology including S0597 nasal, latanoprost plus timolol combination eye drops, dry powder inhaler, Baclofen GRS Capsule and PICN.	965.87

Proposed revised deployment of funds:

(₹ in million)

Sr. No.	Fund Requirements	Amount	Proposed/ estimated Deployment of Funds		
			March 2013	Fiscal 2014	Fiscal 2015
1.	Pharmaceutical research and development activities - Funding clinical trials in India or USA, on any existing and/or future product/technology including S0597 nasal, latanoprost plus timolol combination eye drops, dry powder inhaler, Baclofen GRS Capsule and PICN.	965.87	35.00	415.00	515.87

Section 61 of the Companies Act, 1956 provides that the Company shall not vary the terms of a contract under the prospectus or statement in lieu of prospectus, except subject to the approval of, or except on authority given by, the Company in a general meeting. Since the Letter of Offer of the Company is akin to a Prospectus and the objects of the issue are akin to the terms of the contract/agreement, section 61 is applicable here and accordingly the approval of members is being sought to alter the utilisation of funds out of the Proceeds of a Rights Issue. Accordingly, approval of members is sought to confer authority in favour of the Board for utilisation of the unutilised portion of the proceeds of the Rights Issue for purposes other than those stated in the Letter of Offer.

Your Directors therefore recommend the resolution proposed at Item no. 1 to be passed as special resolution by the members.

None of the Directors is in any way concerned or interested in the above resolution except to the extent of their respective shareholding, or the shareholdings of the Companies/Institutions of which they are Directors and/or Members.

By order of the Board
For Sun Pharma Advanced Research Company Ltd.,

Sd/-
Meetal S. Sampat
Company Secretary

Registered Office:
SPARC, Akota Road, Akota,
Vadodara - 390 020.

Place: Mumbai

Date: 2nd April, 2013

Encl.: 1. Postal Ballot Form
2. Self addressed postage pre-paid envelope.